Patent application number | Description | Published |
20090054415 | COMBINATIONS, METHODS AND COMPOSITIONS FOR TREATING CANCER - The invention relates to a combination of BCR-ABL inhibitor, exemplified by ‘N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide and/or other BCR/ABL inhibitors, and a stem cell selective cytotoxic, exemplified by (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile, hydrochloride salt, and or other stem cell cytotoxic agents, pharmaceutical compositions of the combination and to methods of using the pharmaceutical compositions in the treatment of oncological disorders. | 02-26-2009 |
20090093495 | COMBINATION OF A SRC KINASE INHIBITOR AND A BCR-ABL INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE DISEASES - A combination and methods are disclosed which are useful for the treatment of cancer and/or leukemia. | 04-09-2009 |
20090099197 | Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof - The invention described herein relates to diagnostic and treatment methods and compositions useful in the management of disorders, for example cancers, involving cells that overexpress MDR-1, and methods of decreasing the incidence of CNS complications that are often associated with CML patients that have been administered imatinib or other protein tyrosine kinase inhibitors. | 04-16-2009 |
20090163510 | Methods of Identifying and Treating Individuals Exhibiting Mutant SRC Kinase Polypeptides - The invention described herein relates to mutant SRC kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant SRC kinase proteins. | 06-25-2009 |
20090215792 | METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA CELLS - Here, the inventors disclose the treatment of imatinib mesylate resistant chronic myelogenous leukemia cells with a cotreatment of vorinostat (SAHA, suberoylanilide hydroxamic acid) and dasatinib, a dual Abl/Src kinase (TK) inhibitor. Combined treatment of cultured human CML and BaF3 cells with vorinostat and dasatinib induced more apoptosis than either agent alone, as well as synergistically induced loss of clonogenic survival, which was associated with greater depletion of Bcr-Abl, p-CrkL and p-STAT5 levels. Co-treatment with dasatinib and vorinostat also attenuated the levels of Bcr-AblE255K and Bcr-AblT315I and induced apoptosis of BaF3 cells with ectopic expression of the mutant forms of Bcr-Abl. Finally, co-treatment of the primary CML cells with vorinostat and dasatinib induced more loss of cell viability and depleted Bcr-Abl or Bcr-AblT315I, p-STAT5 and p-CrkL levels than either agent alone. | 08-27-2009 |
20090221601 | Methods of identifying and treating individuals exhibiting mutant kit protein - The invention described herein relates to methods of identifying and treating individuals with protein tyrosine kinase associated disorders that have, or may, become resistant to treatment with a kinase inhibitor such as imatinib due to a gain-of-function mutation in KIT tyrosine kinase. | 09-03-2009 |
20090258937 | Methods for Modulating Tumor Growth and Metastasis - Methods and pharmaceutical compositions for modulating tumor growth or metastasis are provided. | 10-15-2009 |
20090270465 | USE OF EPOTHILONE D IN TREATING TAU-ASSOCIATED DISEASES INCLUDING ALZHEIMER'S DISEASE - Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease. | 10-29-2009 |
20090306094 | Methods Of Identifying And Treating Individuals Exhibiting Mutant Bcr/Abl Kinase Polypeptides - The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins. | 12-10-2009 |
20100029676 | T315A AND F317I MUTATIONS OF BCR-ABL KINASE DOMAIN - The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins. | 02-04-2010 |
20100098701 | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 04-22-2010 |
20100173426 | BIOMAKER IDENTIFYING THE REACTIVATION OF STAT3 AFTER SRC INHIBITION - A method of identifying cancer or an associated disorder comprising identifying and quantifying STAT3 occurring in a biological sample taken from a subject after administering a SFK inhibitor to said subject. | 07-08-2010 |
20110112155 | METHODS FOR TREATING CANCER IN PATIENTS HAVING BREAST CANCER RESISTANCE PROTEIN OVEREXPRESSION - A method for treating cancer comprising identifying a mammal that overexpresses breast cancer resistance protein; and administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of ixabepilone. In one aspect, the mammal is not administered an agent that is susceptible to breast cancer resistance protein overexpression resistance. In another aspect, the cancer is breast and/or lung cancer. | 05-12-2011 |
20110230528 | Use of Epothilone D in Treating Tau-Associated Diseases Including Alzheimer's Disease - Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease. | 09-22-2011 |
20120121604 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. Such Compositions comprise inter alia an anti-CTLA-4 agent, e.g. ipilimumab or tremelimumab in combination with other chemotherapeutic agents such as dasatinib, imatinib, paclitaxel, gemcitabine, cisplatin or etoposide. | 05-17-2012 |
20120135001 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DASATINIB FOR THE TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 05-31-2012 |
20120245151 | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS - Disclosed are compounds of Formula (I) or prodrugs thereof; | 09-27-2012 |
20130012519 | Biomarker Identifying the Reactivation of STAT3 After Src Inhibition - A method of identifying cancer or an associated disorder comprising identifying and quantifying STAT3 occurring in a biological sample taken from a subject after administering a SFK inhibitor to said subject. | 01-10-2013 |
20130142805 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 06-06-2013 |
20140087992 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF - Disclosed are compounds of Formula (I) and/or salts thereof: | 03-27-2014 |
20140100365 | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS - Disclosed are compounds of Formula (I) or prodrugs thereof; | 04-10-2014 |
20140135367 | Use of Epothilone D in Treating Tau-Associated Diseases Including Alzheimer's Disease - Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease. | 05-15-2014 |
20140141024 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 05-22-2014 |